Raws li Fierce Pharma (Tsib Hlis 11, 2026),
CSL txo qis qhov kev kwv yees nyiaj tau los thiab yuav siv $ 5B kev puas tsuaj raws li tus thawj coj ua haujlwm ib ntus R&D ploj lawm, kev lag luam yaig. Yog xav paub ntxiv, thov mus saib daim ntawv tshaj tawm thawj:https://www.fiercepharma.com/pharma/csl-slashes-revenue-projection-4-and-takes-5b-impairment